Header Logo

Connection

MILIND JAVLE to Aged

Back to Details
This is a "connection" page, showing publications MILIND JAVLE has written about Aged.
MILIND JAVLE
Connection Strength
0.994
Aged
  1. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 10; 6(10):803-815.
    View in: PubMed
    Score: 0.033
  2. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 09; 22(9):1290-1300.
    View in: PubMed
    Score: 0.033
  3. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials. JAMA Oncol. 2021 May 01; 7(5):693-699.
    View in: PubMed
    Score: 0.033
  4. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep. 2020 12 16; 10(1):22087.
    View in: PubMed
    Score: 0.032
  5. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
    View in: PubMed
    Score: 0.027
  6. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 2018 01 20; 36(3):276-282.
    View in: PubMed
    Score: 0.026
  7. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810.
    View in: PubMed
    Score: 0.025
  8. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
    View in: PubMed
    Score: 0.021
  9. Biomarkers of TGF-? signaling pathway and prognosis of pancreatic cancer. PLoS One. 2014; 9(1):e85942.
    View in: PubMed
    Score: 0.020
  10. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014 Apr; 45(4):701-8.
    View in: PubMed
    Score: 0.020
  11. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14; 10:368.
    View in: PubMed
    Score: 0.016
  12. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009 Jun 16; 100(12):1842-5.
    View in: PubMed
    Score: 0.014
  13. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Invest. 2009 Feb; 27(2):193-200.
    View in: PubMed
    Score: 0.014
  14. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol. 2008 Aug; 31(4):329-34.
    View in: PubMed
    Score: 0.014
  15. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007 Dec; 14(12):3527-33.
    View in: PubMed
    Score: 0.013
  16. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007 Sep-Oct; 27(5B):3465-70.
    View in: PubMed
    Score: 0.013
  17. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol. 2007 Nov; 14(11):3202-9.
    View in: PubMed
    Score: 0.013
  18. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology. 2007 Jul-Aug; 54(77):1339-44.
    View in: PubMed
    Score: 0.013
  19. Cystic pancreatic tumors (CPT): predictors of malignant behavior. J Surg Oncol. 2007 Mar 01; 95(3):221-8.
    View in: PubMed
    Score: 0.012
  20. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J. 2007 Mar-Apr; 13(2):119-24.
    View in: PubMed
    Score: 0.012
  21. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol. 2006 Nov; 21(11):1744-51.
    View in: PubMed
    Score: 0.012
  22. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006 Jul; 13(7):933-9.
    View in: PubMed
    Score: 0.012
  23. Primary esophageal lymphoma: case series and review of the literature. Dig Dis Sci. 2006 Jan; 51(1):77-83.
    View in: PubMed
    Score: 0.011
  24. Management of locoregional stage esophageal cancer: a single center experience. Dis Esophagus. 2006; 19(2):78-83.
    View in: PubMed
    Score: 0.011
  25. Chemoradiation is a tolerable therapy for older adults with esophageal cancer. Anticancer Res. 2005 Jul-Aug; 25(4):3055-60.
    View in: PubMed
    Score: 0.011
  26. Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study? Am J Clin Oncol. 2005 Feb; 28(1):30-5.
    View in: PubMed
    Score: 0.011
  27. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology. 2004 Nov-Dec; 51(60):1653-7.
    View in: PubMed
    Score: 0.010
  28. Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? Dis Esophagus. 2004; 17(2):129-35.
    View in: PubMed
    Score: 0.010
  29. Unusual locations of involvement by malignancies: Case 3. Gastric signet ring carcinoma presenting as a diffuse thigh mass. J Clin Oncol. 2003 Sep 01; 21(17):3371-3.
    View in: PubMed
    Score: 0.010
  30. Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma. Surg Oncol. 2022 Mar; 40:101696.
    View in: PubMed
    Score: 0.009
  31. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology. 2022 02; 75(2):297-308.
    View in: PubMed
    Score: 0.009
  32. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. JCO Precis Oncol. 2021 08; 5.
    View in: PubMed
    Score: 0.008
  33. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050.
    View in: PubMed
    Score: 0.008
  34. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813.
    View in: PubMed
    Score: 0.008
  35. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192.
    View in: PubMed
    Score: 0.008
  36. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839.
    View in: PubMed
    Score: 0.008
  37. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020 09; 21(9):1234-1243.
    View in: PubMed
    Score: 0.008
  38. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415.
    View in: PubMed
    Score: 0.008
  39. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002.
    View in: PubMed
    Score: 0.008
  40. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020 06; 21(6):796-807.
    View in: PubMed
    Score: 0.008
  41. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 12; 38(6):1763-1773.
    View in: PubMed
    Score: 0.008
  42. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1).
    View in: PubMed
    Score: 0.008
  43. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504.
    View in: PubMed
    Score: 0.008
  44. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394.
    View in: PubMed
    Score: 0.007
  45. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
    View in: PubMed
    Score: 0.007
  46. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):824-830.
    View in: PubMed
    Score: 0.007
  47. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
    View in: PubMed
    Score: 0.007
  48. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018 11 06; 16(1):300.
    View in: PubMed
    Score: 0.007
  49. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer. 2019 02 01; 125(3):463-472.
    View in: PubMed
    Score: 0.007
  50. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol. 2019 Feb; 26(2):619-627.
    View in: PubMed
    Score: 0.007
  51. A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies. Cancer. 2018 10 01; 124(19):3890-3899.
    View in: PubMed
    Score: 0.007
  52. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
    View in: PubMed
    Score: 0.007
  53. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
    View in: PubMed
    Score: 0.007
  54. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Invest New Drugs. 2018 12; 36(6):1037-1043.
    View in: PubMed
    Score: 0.007
  55. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
    View in: PubMed
    Score: 0.007
  56. Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension. Oncologist. 2018 06; 23(6):712-718.
    View in: PubMed
    Score: 0.007
  57. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26.
    View in: PubMed
    Score: 0.007
  58. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056.
    View in: PubMed
    Score: 0.006
  59. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
    View in: PubMed
    Score: 0.006
  60. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
    View in: PubMed
    Score: 0.006
  61. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer. Br J Cancer. 2017 Mar 14; 116(6):697-702.
    View in: PubMed
    Score: 0.006
  62. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039.
    View in: PubMed
    Score: 0.006
  63. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer. Br J Surg. 2017 Feb; 104(3):267-277.
    View in: PubMed
    Score: 0.006
  64. Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. Cancer. 2017 04 15; 123(8):1354-1362.
    View in: PubMed
    Score: 0.006
  65. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017.
    View in: PubMed
    Score: 0.006
  66. Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy? Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):323-332.
    View in: PubMed
    Score: 0.006
  67. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985.
    View in: PubMed
    Score: 0.006
  68. Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance. Cancer. 2016 12 01; 122(23):3657-3666.
    View in: PubMed
    Score: 0.006
  69. Laparoscopic Management of Gallbladder Cancer: A Stepwise Approach. Ann Surg Oncol. 2016 12; 23(Suppl 5):892-893.
    View in: PubMed
    Score: 0.006
  70. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget. 2016 Jun 07; 7(23):35302-12.
    View in: PubMed
    Score: 0.006
  71. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9.
    View in: PubMed
    Score: 0.006
  72. Somatic Mutations of PI3K in Early and Advanced Gallbladder Cancer: Additional Options for an Orphan Cancer. J Mol Diagn. 2016 05; 18(3):388-394.
    View in: PubMed
    Score: 0.006
  73. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol. 2016 Feb 10; 34(5):460-8.
    View in: PubMed
    Score: 0.006
  74. Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15; 94(4):755-65.
    View in: PubMed
    Score: 0.006
  75. Transarterial chemoembolization in a patient with recurrent hepatocellular carcinoma and portal vein thrombosis: a case report and review of the literature. Am J Clin Oncol. 2005 Dec; 28(6):638-9.
    View in: PubMed
    Score: 0.006
  76. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2016 Jan 20; 34(3):219-26.
    View in: PubMed
    Score: 0.006
  77. Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. J Clin Pathol. 2016 May; 69(5):403-8.
    View in: PubMed
    Score: 0.006
  78. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S1221-8.
    View in: PubMed
    Score: 0.006
  79. Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer. Diagn Pathol. 2015 Aug 21; 10:148.
    View in: PubMed
    Score: 0.006
  80. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2015 Sep; 76(3):489-498.
    View in: PubMed
    Score: 0.005
  81. Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015 Apr; 261(4):733-9.
    View in: PubMed
    Score: 0.005
  82. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol. 2015 Jul; 54(7):971-8.
    View in: PubMed
    Score: 0.005
  83. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9.
    View in: PubMed
    Score: 0.005
  84. Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 2014 Apr; 124(4):1525-36.
    View in: PubMed
    Score: 0.005
  85. High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: a single center retrospective study. Thromb Res. 2014 Feb; 133(2):154-7.
    View in: PubMed
    Score: 0.005
  86. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83.
    View in: PubMed
    Score: 0.005
  87. Role of endoscopic ultrasonography in evaluation of metastatic lesions to the pancreas: a tertiary cancer center experience. Pancreas. 2013 Apr; 42(3):516-23.
    View in: PubMed
    Score: 0.005
  88. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
    View in: PubMed
    Score: 0.005
  89. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointest Endosc. 2012 Feb; 75(2):332-8.
    View in: PubMed
    Score: 0.004
  90. Radiation treatment outcomes for unresectable hepatocellular carcinoma. Acta Oncol. 2011 Nov; 50(8):1191-8.
    View in: PubMed
    Score: 0.004
  91. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci. 2011 Dec; 56(12):3678-84.
    View in: PubMed
    Score: 0.004
  92. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
    View in: PubMed
    Score: 0.004
  93. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial. Ann Surg Oncol. 2011 Dec; 18(13):3615-22.
    View in: PubMed
    Score: 0.004
  94. Optimum palliation of inoperable hilar cholangiocarcinoma: comparative assessment of the efficacy of plastic and self-expanding metal stents. Dig Dis Sci. 2011 May; 56(5):1557-64.
    View in: PubMed
    Score: 0.004
  95. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer. 2010 Nov 15; 116(22):5325-35.
    View in: PubMed
    Score: 0.004
  96. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 2010 Aug; 139(2):464-73, 473.e1-3.
    View in: PubMed
    Score: 0.004
  97. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer. 2010 Apr 15; 116(8):1938-46.
    View in: PubMed
    Score: 0.004
  98. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. Oncology. 2010; 78(2):125-9.
    View in: PubMed
    Score: 0.004
  99. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.004
  100. Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res. 2010 Jan 01; 16(1):320-9.
    View in: PubMed
    Score: 0.004
  101. Reirradiation to the abdomen for gastrointestinal malignancies. Radiat Oncol. 2009 Nov 18; 4:55.
    View in: PubMed
    Score: 0.004
  102. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors. Anticancer Res. 2009 Oct; 29(10):4127-30.
    View in: PubMed
    Score: 0.004
  103. Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen. Int J Radiat Oncol Biol Phys. 2010 Mar 15; 76(4):1193-8.
    View in: PubMed
    Score: 0.004
  104. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol. 2009 Apr; 63(5):851-7.
    View in: PubMed
    Score: 0.003
  105. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol. 2007 Aug; 30(4):350-7.
    View in: PubMed
    Score: 0.003
  106. A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clin Cancer Res. 2007 Apr 01; 13(7):2091-9.
    View in: PubMed
    Score: 0.003
  107. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg. 2007 Apr; 11(4):445-51.
    View in: PubMed
    Score: 0.003
  108. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival. Ann Surg Oncol. 2007 Feb; 14(2):752-8.
    View in: PubMed
    Score: 0.003
  109. Gallbladder cancer: Defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol. 2007 Feb; 14(2):833-40.
    View in: PubMed
    Score: 0.003
  110. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol. 2007 Apr; 59(5):581-7.
    View in: PubMed
    Score: 0.003
  111. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. J Chemother. 2006 Oct; 18(5):514-24.
    View in: PubMed
    Score: 0.003
  112. Regular aspirin use and esophageal cancer risk. Int J Cancer. 2006 Jul 01; 119(1):202-7.
    View in: PubMed
    Score: 0.003
  113. Combined hepatocholangiocarcinoma: case-series and review of literature. Int J Gastrointest Cancer. 2006; 37(1):27-34.
    View in: PubMed
    Score: 0.003
  114. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol. 2005 Dec; 28(6):560-4.
    View in: PubMed
    Score: 0.003
  115. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin Cancer Res. 2005 Nov 01; 11(21):7794-9.
    View in: PubMed
    Score: 0.003
  116. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res. 2005 Aug 15; 11(16):5942-9.
    View in: PubMed
    Score: 0.003
  117. Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma. Int J Gastrointest Cancer. 2005; 35(3):171-7.
    View in: PubMed
    Score: 0.003
  118. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus. 2005; 18(6):400-5.
    View in: PubMed
    Score: 0.003
  119. Anaplastic pancreatic carcinoma. A case report and review of literature . JOP. 2004 Nov 10; 5(6):512-5.
    View in: PubMed
    Score: 0.003
  120. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004 May-Jun; 8(4):448-53.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.